Newsfile Corp
23 Aug 2026, 10:45 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
The FDA has placed a full clinical hold on Aardvark Therapeutics' investigational new drug application (IND) for ARD-101, affecting all ongoing clinical studies including the Phase 3 HERO trial. — A full FDA clinical hold is a severe regulatory setback that halts development and significantly diminishes the probability of drug approval.
-0.90Aardvark Therapeutics is facing a federal securities class action lawsuit alleging the company made false and misleading statements regarding the safety and prospects of ARD-101. — Securities litigation introduces significant legal liability, potential financial settlements, and reputational damage to the company.
-0.60Aardvark voluntarily paused the Phase 3 HERO trial after observing reversible cardiac issues at above-target therapeutic doses in a healthy volunteer study. — Safety signals involving cardiac observations suggest a high risk profile for the lead asset, increasing the likelihood of failure or restrictive labeling.
-0.50Continue reading
6 related stories
Top 1 mover · tap to explore
Which stocks this story touches
The company is facing a federal securities class action lawsuit following a clinical hold by the FDA and a massive drop in stock price.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Newsfile Corp
2h ago
